Actively Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Led by Revolution Medicines, Inc. · Updated on 2026-02-04
574
Participants Needed
5
Research Sites
142 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
CONDITIONS
Official Title
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
- Received and progressed or been intolerant to prior standard therapy appropriate for tumor type and stage.
- Measurable disease per RECIST v1.1 criteria.
- Adequate organ function including bone marrow, liver, kidney, and coagulation.
- Able to take oral medications.
You will not qualify if you...
- Primary central nervous system (CNS) tumors.
- Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy such as degraders or inhibitors.
- Any condition affecting the ability to take or absorb the study drug.
- Major surgery within 28 days prior to receiving study drug(s).
- Inability or unwillingness to comply with study visits or procedures.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
2
NEXT - Dallas
Dallas, Texas, United States, 75039
Actively Recruiting
3
NEXT
San Antonio, Texas, United States, 78229
Actively Recruiting
4
START - San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
5
NEXT - Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
R
Revolution Medicines Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here